Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Compounds in development (PDF 0.1 MB) section of the 2025 Annual Report  

Show Filters
Oncology: Solid TumorsX
Clear All
Showing 23 results
  • AAA601
    Lutathera®
    Gastroenteropancreatic neuroendocrine tumors
    Oncology: Solid Tumors Phase 3 2028 Radioligand therapy target SSTR
    Supplementary Indication
  • AAA601
    Lutathera®
    GEPNET, pediatrics
    Oncology: Solid Tumors Phase 2 Radioligand therapy target SSTR
  • AAA614
    AAA614
    Solid tumors
    Oncology: Solid Tumors Phase 2 Radioligand therapy target FAP
    Lead Indication
  • AAA617
    Pluvicto®
    Oligometastatic prostate cancer
    Oncology: Solid Tumors Phase 3 ≥ 2029 Radioligand therapy target PSMA
    Supplementary Indication
  • AAA617
    Pluvicto®
    Metastatic hormone sensitive prostate cancer (mHSPC)
    Oncology: Solid Tumors Registration Radioligand therapy target PSMA
    Supplementary Indication
  • AAA817
    225Ac-PSMA-617
    Metastatic castration-resistant prostate cancer (mCRPC)
    Oncology: Solid Tumors Phase 3 ≥ 2029 Radioligand therapy target PSMA
    Supplementary Indication
  • AAA817
    225Ac-PSMA-617
    post Lu Metastatic castration-resistant prostate cancer (mCRPC)
    Oncology: Solid Tumors Phase 3 2028 Radioligand therapy target PSMA
    Lead Indication
  • AMO959
    AMO959
    Prostate cancer
    Oncology: Solid Tumors Phase 1 DNA PK inhibitor
    Lead Indication
  • BYL719
    Vijoyce®
    Lymphatic malformations
    Oncology: Solid Tumors Phase 3 ≥ 2029 PI3K-alpha inhibitor
    Supplementary Indication
  • DJI136
    DJI136
    Small cell lung cancer
    Oncology: Solid Tumors Phase 1 DLL3 CAR-T
    Lead Indication
  • DZR123
    tulmimetostat
    Metastatic prostate cancer
    Oncology: Solid Tumors Phase 1 EZH1, EZH2 inhibitor
  • DZR123
    tulmimetostat
    Solid tumors & lymphomas
    Oncology: Solid Tumors Phase 2 EZH1, EZH2 inhibitor
    Lead Indication
  • ECI830
    ECI830
    Breast cancer
    Oncology: Solid Tumors Phase 1 CDK2 inhibitor
    Lead Indication
  • ESP359
    225Ac-ETN029
    Solid tumors
    Oncology: Solid Tumors Phase 1 Radioligand therapy target DLL3
    Lead Indication
  • FML539
    177Lu-DWJ155
    Solid tumors
    Oncology: Solid Tumors Phase 1 Radioligand therapy target HER2
    Lead Indication
  • FXX489
    177Lu-NNS309
    Solid tumors
    Oncology: Solid Tumors Phase 1 Radioligand therapy target FAP
    Lead Indication
  • GCJ904
    GCJ904
    Solid tumors
    Oncology: Solid Tumors Phase 1
    Lead Indication
  • GVV858
    GVV858
    Breast cancer and other advanced solid tumors
    Oncology: Solid Tumors Phase 1
    Lead Indication
  • IEV407
    IEV407
    Breast cancer
    Oncology: Solid Tumors Phase 1
    Lead Indication
  • INR731
    INR731
    Prostate cancer
    Oncology: Solid Tumors Phase 1
    Lead Indication
Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.